Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
Published Time:
2024-11-18 18:09
Source:
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
Hidden Unicorns—a new concept—represent high-potential enterprises critical to sci-tech cultivation. The report, the fourth of its kind, uses the Global Unicorn 500 database and Hidden Unicorn evaluation criteria (requiring original/disruptive technologies and irreplicable business models). Through AI-augmented analysis, the top 500 Hidden Unicorns in China were selected.
Since its founding, Jiangsu Vcare has focused on innovative drugs and advanced therapies, evolving into a dual-core enterprise (innovative drug R&D + full-chain CRO/CDMO services). It currently has5 clinical-stage Class I innovative drug projectsand10+ preclinical projects, with a pipeline centered on Vicagrel covering cardiovascular, oncology, and autoimmune diseases. Its CRO/CDMO arm serves 300+ global clients, operating the 130-mu (approx. 8.67 hectares) CDMO facility—Hubei Tianshu Pharmaceutical Co., Ltd.in a provincial chemical park—providing integrated services from advanced intermediates to APIs, and from CMC to clinical CRO and registration.
This recognition affirms Jiangsu Vcare’s "hardcore" R&D strength and future potential. The company will implement a "new quality productivity" strategy, advancing its dual-core model (innovative drugs + full-chain CRO/CDMO) to become a top-tier global pharmaceutical group.
Related News
20
2023
/
01
I. Corporate Development and Infrastructure ① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd. ② CDMO Business Technology Center completed and operational. ③ Established new technology platform laboratories. ④ Built a new Innovative Drug Synthesis Technology Center.
View Details
27
2022
/
12
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed a Series B financing round exceeding CNY 200 million,which were led by Changjiang Venture Capital ,with participation from Hongcheng Capital and Hangzhou Huadian Investment, and continued support from Yangtze River Industry Group and SDIC Capital. The raised funds will be used to accelerate the clinical development of the company's core innovative drug products and the construction of its CDMO industrial base.
View Details
19
2022
/
05
Recently, Vicagrel capsules, a Class 1 novel antiplatelet agent developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received Clinical Trial Approval from the NMPA for the target indication of minor ischemic stroke (MIS) or transient ischemic attack (TIA). The related Phase II clinical trial is set to begin shortly.
View Details
06
2022
/
05
Jiangsu Vcare Closes Series A2 Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.
View Details
22
2021
/
11
On November 19, 2021, the first clinical trial participant was dosed with VC005 tablets, a highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The dosing was completed at the Phase I Clinical Research Center of the First Hospital of Jilin University, and the participant has now successfully completed the safety observation period.
View Details
18
2021
/
08
Initiation Meeting of FDA-FE Clinical Study of Vicagrel Capsules
On August 18, the kick-off meeting of the FDA-FE clinical study of Vicagrel Capsules, a Class I new drug of Jiangsu Vcare Pharmatech Co., Ltd. (Jaingsu Vcare), was held at the Phase I Clinical Research Center of the First Hospital of Jilin University. This marks the official launch of the FDA clinical study of Vicagrel in the United States and the supporting Phase III clinical study in China.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn